Navigation Links
Angiotech's Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
Date:8/11/2009

rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly report for the three months ended June 30, 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

    (C)2009 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

    About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: '/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference
2. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
3. Tutogen Medical, Inc. to Report Fourth Quarter and Fiscal Year 2007 Financial Results
4. Tutogen Medical, Inc. Reports Year-End Fiscal 2007 Financial Results
5. Nonin Medical, Inc. Receives Frost & Sullivans 2007 Award for Product Differentiation Innovation
6. Tutogen Medical, Inc. Reports First Quarter Fiscal 2008 Financial Results
7. Arobella Medical, LLC Launches Qoustic Wound Therapy System(TM)
8. SBT Acquisition Inc. Successfully Completes Tender Offer for Shares of Lifecore Biomedical, Inc.
9. Tryton Medical, Inc. Closes $14 Million Financing
10. China Sky One Medical, Inc. Acquires Heilongjiang Haina Pharmaceutical Inc.
11. Cohera Medical, Inc. Announces Closing of Insider Round of Financing for Over $7.6 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... Texas , May 29, 2015  Caris ... focused on fulfilling the promise of precision medicine, ... studies that demonstrate the clinical utility of Caris ... tumor profiling service, in helping to identify targeted ... tumors. In each of the studies, results of ...
(Date:5/29/2015)... 29, 2015 Seoul Semiconductor (CEO: ... LED technology, on May 28th announced that it ... by strengthening its high efficient and high reliable ... Since 2011 Seoul Semiconductor has developed efficient and ... and has supplied LEDs for headlamps to global ...
(Date:5/28/2015)... May 28, 2015  Quest Diagnostics Incorporated (NYSE: ... services, announced that it is scheduled to speak at ... Steve Rusckowski , the company,s President and CEO, ... strategy.  The presentation is scheduled for Tuesday, June 2, ... presentation will be webcast live during the conference and ...
(Date:5/28/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/6cg3zw/cell_therapy ) has announced ... "Cell Therapy - Technologies, Markets and Companies" ... and evaluates cell therapy technologies and methods, which ... in the practice of medicine. Hematopoietic stem cell ... transplants. Role of cells in drug discovery is ...
Breaking Biology Technology:Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 2Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 3Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 4Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 5Multi-Platform Tumor Profiling from Caris Life Sciences Identifies Targeted Treatment Options for Patients with Rare and/or Aggressive Tumors 6Seoul Semiconductor Increases the Global Automotive LED Market Share with its High Efficient and Reliable LEDs for Automotive Lightings 2Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference 2Global Cell Therapy Market 2015-2020 - Technologies, Markets and Companies 2
... Genoptix, Inc.,(Nasdaq: GXDX ), a specialized ... the BIOCOM Investor Conference 2008,scheduled to take place ... on October,26-28, 2008., Dr. Tina Nova, President ... on Monday, October 27, beginning at approximately 9:30 ...
... ... - Results Presented at the 20th EORTC-NCI-AACR Symposium on Molecular ... Targets and Cancer Therapeutics -, GENEVA and SAN FRANCISCO, ... new data from an,ongoing Phase 1-2 clinical trial demonstrating that the Company,s novel,androgen ...
... Presented at 20th EORTC-NCI-AACR Symposium -, ... 22 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: ... today announced positive incremental data from,its randomized, ... in patients,with metastatic colorectal cancer (CRC). The ...
Cached Biology Technology:Genoptix Announces Participation at the BIOCOM Investor Conference 2008 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 2Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 3Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 4Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer 5
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/27/2015)... , Apr. 27, 2015 Profile Solutions, Inc. ... and security systems is pleased to announce that Dr ... a consultant and member of its scientific advisory board. ... known as a thought leader in technology-enhanced learning models. ... Group, and has published studies and books focused on ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... Testing people for heart disease might be just a finger ... by a team of researchers from Harvard and Northeastern universities ... FASEB Journal ( http://www.fasebj.org ), they describe how ... needed to build vascular tissue, called endothelial progenitor cells, using ...
... Boston, MA June 1, 2009 REGiMMUNE ... in combination with a low-dose of Sirolimus, demonstrated enhanced ... transplantation and acute Graft-versus-Host disease (GvHD). This data ... Tolerance Induction by a Liposomal Formulation of KRN7000 (RGI-2001) ...
... species are likely to respond to climate change. Most ... and the interactions between species, in the interest of ... BioScience , by Eric Post of Pennsylvania State University ... avoided. Their approach, which relies on multi-stage analyses of ...
Cached Biology News:New device detects heart disease using less than one drop of blood 2REGiMMUNE presents enhanced efficacy data in preclinical transplantation models 2
Buckets for tube holder inserts...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
... 10-2 is a microprocessor controlled, high ... coupled with exceptionally smooth operation make ... applications involving fluorescence microscopy, ratio imaging, ... requiring rapid and accurate aperture positioning. ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: